Skip to content

Application Research of Different doses of Tigillidine fumarate in Gastrointestinal Tumor surgery

Application Research of Different doses of Tigillidine fumarate in Gastrointestinal Tumor surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600125744
Enrollment
Unknown
Registered
2026-05-29
Start date
2026-05-30
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative pain after gastrointestinal tumor surgery

Interventions

group A:0.5mg Teliglidine combined with analgesia
group B:0.75mg Teliglidine combined with analgesia

Sponsors

Affiliated Qingyuan Hospital, Guangzhou Medical University,Qingyuan People's Hospital;
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Patients with gastrointestinal tumors scheduled for surgery; 2.Age 18 years old or above; 3.BMI:18-30kg/m^2; 4.The estimated duration of the surgery is no more than 4 hours. 5.ASA classification levels II to III; 6.No cognitive impairment; 7.Voluntarily sign the informed consent form and be willing to comply with the requirements of the plan;

Exclusion criteria

Exclusion criteria: 1.For studies involving drug allergies, severe hypoxia, and bronchial asthma; 2.Patients with abnormal coagulation function; 3.Abuse or prolonged use of anesthetic, sedative, and analgesic drugs; 4.Cognitive dysfunction, language and hearing impairments; 5.Patients with long-term chronic pain; 6. Patients with severe liver and kidney dysfunction

Design outcomes

Primary

MeasureTime frame
Pain Visual Rating Scale;

Secondary

MeasureTime frame
Vital signs: Mean arterial pressure (MAP), heart rate (HR), fingertip pulse oxygen saturation (SPO2%);

Countries

China

Contacts

Public ContactXiaodan Liu

Affiliated Qingyuan Hospital, Guangzhou Medical University,Qingyuan People's Hospital;

475019480@qq.com+86 763 641 1032

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026